Form 4: X4 Pharmaceuticals CFO Adam S. Mostafa Sells 52,500 Shares
SEC Form 4 Filing
Adam S. Mostafa, CFO of X4 Pharmaceuticals, sold 52,500 shares of common stock at a weighted average price of $0.8828 on March 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On March 11, 2024, Adam S. Mostafa, the Chief Financial Officer of X4 Pharmaceuticals, Inc., sold 52,500 shares of common stock.
- The sale was executed at a weighted average price of $0.8828 per share.
- The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023.
- The price range for the shares sold was between $0.8649 and $0.9147.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction was pre-planned under a Rule 10b5-1 trading plan and doesn't necessarily reflect a change in the CFO's outlook on the company.
Industry Context
Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency when corporate insiders trade their company's stock. The filing is for a relatively small amount of shares.
Key Dates
| Date | Description |
|---|---|
| May 23, 2023 | Date the Rule 10b5-1 trading plan was adopted by Adam S. Mostafa. |
| March 11, 2024 | Date of the stock sale transaction. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.